New hope for liver metastases: immune booster combined with targeted chemo

NCT ID NCT05286814

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 32 times

Summary

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a surgically placed pump that sends chemo only to the liver. The goal is to see if the tumors shrink or stop growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-••••

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex carcinoma adrenal cortex neoplasm adrenal gland cancer adrenal gland neoplasm bile duct cancer bile duct neoplasm cholangiocarcinoma Cirrhosis, Familial, with Pulmonary Hypertension colorectal cancer colorectal neoplasm intrahepatic bile duct cancer intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENAL CORTEX NEOPLASMS ADRENAL CORTICAL CARCINOMA ADRENAL GLAND CANCER ADRENAL GLAND NEOPLASMS ADRENOCORTICAL CARCINOMA (ACC) BILE DUCT CANCER BILE DUCT NEOPLASMS CHOLANGIOCARCINOMA COLORECTAL CANCER COLORECTAL NEOPLASMS INTRAHEPATIC BILE DUCT CANCER INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) METASTATIC COLORECTAL CANCER (MCRC)